After an eye injury from trauma, corneal surgery or a chemical burns, corneal tissues and local immune cells (Leukocytes) generate pro-inflammatory cytokines and prostaglandins that initiate acute pain and increase tissue permeability. Chemokine concentrations, to attract circulating Leukocytes, are also increased as are levels of adhesion molecules to ensure high levels of Leukocytes remain in the inflamed tissue. These effects can be blocked by activation of CB2 receptors that appear in high numbers after corneal injury so that pain and inflammation are controlled. TA-A001 is a CB2 receptor activator which has been shown to produce rapid analgesia in acute pain models including after topical application to the eye.

Should inflammation not be brought under control, due to an infection, as occurs in Keratitis or Uveitis, or in chronic diseases such as Dry Eye Syndrome and Age Related Macular Degeneration (AMD) a vicious cycle develops whereby Leukocytes numbers remain high as do the levels of tissue destructive superoxide, proteases and hypochlorous acid they release; blindness can result.TA-A001 has been shown to break the cycle by reducing Leukocyte levels and levels of pro-inflammatory cytokines and prostaglandins.


Phone: 514 883 3447



TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020